Business Wire

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting

Share

Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021.

“We look forward to presenting data from across Incyte’s oncology portfolio and partner programs at this year’s ASCO Annual Meeting,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Data being presented during this congress, including new three-year data from the L-MIND study of tafasitamab in relapsed or refractory diffuse large B-cell lymphoma as well as results of the OPTIC study of ponatinib in chronic phase-chronic myeloid leukemia, underscore our continued focus on advancing science to help meet patients’ needs.”

Key abstracts accepted by ASCO include:

Oral Presentations

Ponatinib

OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)1(Abstract #7000. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)

Poster Discussions

Tafasitamab

Long-Term Analyses from L-MIND, a Phase 2 Study of Tafasitamab (MOR208) Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)2 (Abstract #7513. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)

Capmatinib

Capmatinib in MET Exon 14-Mutated, Advanced NSCLC: Updated Results from the GEOMETRY Mono-1 Study3(Abstract #9020. Session: Lung Cancer—Non-Small Cell Metastatic.)

ePosters

Capmatinib

Capmatinib Efficacy in Patients with NSCLC Identified as METex14 Using an NGS-Based Liquid Biopsy Assay: Results from the GEOMETRY Mono-1 Study3(Abstract #9111. Session: Lung Cancer—Non-Small Cell Metastatic.)

Patient-Reported Outcomes in Capmatinib-Treated Patients with METex14-Mutated Advanced NSCLC: Results from the Phase 2 GEOMETRY Mono-1 Study3(Abstract #9056. Session: Lung Cancer—Non-Small Cell Metastatic.)

Phase 1b/2 Study of Capmatinib Plus Gefitinib in Patients with EGFR-Mutated, MET-Dysregulated Non–Small Cell Lung Cancer who Received Prior Therapy: Final Overall Survival and Safety3(Abstract #9048. Session: Lung Cancer—Non-Small Cell Metastatic.)

Pemigatinib

Pemigatinib for Previously Treated Locally Advanced/Metastatic Cholangiocarcinoma (CCA): Update of FIGHT-202 (Abstract #4086. Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary.)

Retifanlimab

Phase 2 Study of Retifanlimab (INCMGA00012) in Patients (Pts) with Selected Solid Tumors (POD1UM-203) (Abstract #2571. Session: Developmental Therapeutics—Immunotherapy.)

Ruxolitinib-Parsaclisib Combination Studies

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naïve Myelofibrosis (Abstract #TPS7058. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)

Tafasitamab

A Phase 3 Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) (Abstract #TPS7568. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)

First-MIND: A Phase 1b, Open-Label, Randomized Study to Assess Safety of Tafasitamab (tafa) or Tafa + Lenalidomide (LEN) in Addition to R‑CHOP in Patients with Newly Diagnosed DLBCL2(Abstract #7540. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)

For full session details and data presentation listings, please see the ASCO21 online program at https://meetinglibrary.asco.org. Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, June 4, 2021 at 9:00 a.m. ET.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain and other third-party providers, and development and discovery operations; determinations made by the FDA and other regulatory authorities outside of the United States; the Company’s dependence on its relationships with its collaboration partners; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2020 and the quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.


1 Takeda-sponsored abstract.
2 MorphoSys-sponsored abstract.
3 Novartis-sponsored abstract.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verimatrix Protects Recode Health’s STRIVE Benefits Mobile App16.6.2021 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced its application shielding solutions were selected by Oakland, California-based Recode Health to protect its STRIVE Benefits mobile app. Serving as the SaaS benefits communication platform of choice for thousands of businesses throughout the United States, STRIVE’s mobile app aims to modernize employer-employee relations by seamlessly educating employees so that they stay ahead of the curve and have fingertip access to their benefits guides, balances, financial information and other customizable data. Due to the sensitive nature of the information within the app, such as telemedicine and Rx integrations to save on healthcare costs, the STRIVE management team prioritizes its cybersecurity stance and looked to ensure that its mobile app is as secure as possible. “The protection of employer and employee data is paramount at STRIVE,

Biolog-id Partners With AirMed to Help Enhance Visibility, Availability, and Traceability of Life-saving Blood Components16.6.2021 17:18:00 CEST | Press release

Biolog-id LLC, a developer and service provider of connected healthcare solutions, announced today its partnership with AirMed – one of the first air medical transport programs in the US. As part of this partnership, biolog-id’s cutting-edge technology will provide digital visibility to the inventory of red blood cells and liquid plasma across 5 locations in the state of Utah, covering one of the largest geographical areas in the nation, routinely transporting patients not only from Utah, but also from Colorado, Wyoming, Nevada, Montana, and Idaho. Biolog-id’s blood components management platform will support the inventory replenishment of the different bases, as well as the traceability and documentation of the units selected by the teams at the AirMed bases. “We are pleased to cooperate with the biolog-id team on the deployment of this technology across our operation,” said Cory Cox, AirMed Outreach Coordinator & Flight Paramedic at AirMed. “We are committed to delivering the highest

Moody’s ESG Solutions Launches Bespoke Dataset to Help Market Participants Meet SFDR Requirements16.6.2021 17:10:00 CEST | Press release

Moody’s ESG Solutions today launched a bespoke ESG data solution to help market participants meet the European Union (EU) Sustainable Finance Disclosure Regulation (SFDR) requirements. Harnessing Moody’s ESG Solutions’ analytical rigor and advanced data capture processes, the product was built from the ground up, making it one of only a few purpose-built SFDR data solutions in the market. In effect since March 2021, SFDR introduces disclosure requirements on a set of Principle Adverse Impact (PAI) indicators, which outline the environmental, social and governance (ESG) factors that lead to adverse sustainability impacts. PAI disclosures will become mandatory for all financial market participants, including advisers, from 2022 as part of the EU’s strategy to combat greenwashing and incentivize funding of green projects. “We are committed to advancing sustainability objectives and providing essential data that market participants can rely on,” said Sabine Lochmann, Global Head of Moody’s

Piper Sandler Advises EverArc on its Acquisition of Perimeter Solutions16.6.2021 16:18:00 CEST | Press release

Piper Sandler & Co. chemicals & materials investment banking group (The Valence Group) has advised EverArc Holdings on its announced acquisition of 100% of Perimeter Solutions from SK Capital. EverArc Holdings Limited (LSE: EVRA / EVWA) has entered into a definitive agreement with SK Invictus Holdings S.à.r.l. an affiliate of funds advised by SK Capital Partners, to acquire 100% of SK Invictus Intermediate S.à.r.l., the ultimate parent company of Perimeter Solutions, a leading global manufacturer of high-quality firefighting products and lubricant additives, for total consideration of approximately $2 billion, consisting of cash and preferred shares, subject to customary closing conditions. The transaction is expected to close in Q4 2021. EverArc Holdings Limited (LSE: EVRA / EVWA) is a publicly-listed acquisition company that was formed in November 2019 to undertake an acquisition of a target company or business. Perimeter is a leading global manufacturer of high-quality firefighting

UVD Robots Selected by Global Facility Management Company ISS to Provide Autonomous Disinfection Robots16.6.2021 15:02:00 CEST | Press release

Today, Blue Ocean Robotics the manufacturer of UVD Robots for autonomous UV-C disinfection announced that it was selected by ISS World Services, a world leading global workplace experience and facility management company, to provide autonomous robots for disinfection as part of ISS’ global offering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005504/en/ UVD Robots are helping to ensure outstanding cleaning and disinfection excellence. Unlike many stationary disinfection systems, the UVD Robot is a mobile, fully autonomous robot integrating UV-C light to disinfect against all known bacteria and viruses including Covid-19 not only on surfaces, but the air as well, providing a fully comprehensive infection control and prevention solution. UVD Robots enable facilities to reduce disease transmission by eliminating 99.99 percent of bacteria and viruses in any room. The robots have been rolled out to more than 70 countries

Auth0 Releases State of Secure Identity Report, Highlighting the Most Pervasive Threats to Digital Identities16.6.2021 15:01:00 CEST | Press release

Auth0, the modern identity platform, today announced the launch of its inaugural security report: The State of Secure Identity. This detailed report highlights key areas of concern for security professionals responsible for managing digital identities, including the exponential rise of credential stuffing attacks (automated attempts to compromise a large number of user accounts with stolen credentials), fraudulent registrations, and the widespread use of breached credentials. Recent headlines and high-profile cyber attacks give today’s security professionals a wide swath of serious threats to worry about. The primary goal of cybercriminal activity is to access critical resources, systems, and personal data, yet systems that can be put into place to minimize the risk of attack — like identity management — often get deprioritized. Lack of budget, resourcing, or attention on managing digital identities give threat actors a prime opportunity to take advantage of these discrepancies and sur

Ray Fernandez-Andes Named CFO at Next Level Aviation16.6.2021 15:00:00 CEST | Press release

Seasoned finance executive Ray Fernandez-Andes has been named Chief Financial Officer at Next Level Aviation, a leader in the global distribution of used serviceable material (USM) for commercial aircraft and jet engines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005177/en/ Ray Fernandez-Andes has been named Chief Financial Officer of Next Level Aviation. He will help create financial strategies to support the company’s planned growth in the coming years, both organically and through acquisition. (Photo: Business Wire) Fernandez-Andes brings a high level of finance expertise in the airline and commercial aviation aftermarket to NLA. He has extensive experience in improving financial results, providing strategic advice for growth and capital deployment, as well as managing banking and investor relationships. Fernandez-Andes is a certified public accountant (CPA) in the state of Florida, and a former auditor at Arth